Value
9.0/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.2 |
| P/S | 9.3 |
| EV/EBITDA | 9.5 |
| Fwd P/E | 9.4 |
| PEG | 10.0 |
| Analyst target | 7.5 |
- ▸Forward P/E: 9.5x
- ▸PEG: 0.10
- ▸Attractively valued
NUTX · Why this verdict
Why Nutex Health (NUTX) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score7.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Nutex Health is a high-quality business with excellent ROE (54%) and cash conversion (175% FCF/NI), backed by a perfect Piotroski F-Score of 9/9. Quality breakdown | ROE should stay above 40% and the Piotroski F-Score should hold at 8 or above over the next 12 months to confirm quality durability. | →Stable |
| CounterExtremely high ROE at a $1.4B market cap in a niche healthcare facility model can reflect leverage or a concentrated reimbursement mix rather than a durable moat, and could compress quickly if payer rates shift. | ||
At the current price near its 52-week high, the risk/reward has compressed to just 9.1% modeled upside against 15% downside, an asymmetry ratio of only 0.61 that failed the engine's 1.5 minimum threshold. Reward-to-risk math | Asymmetry ratio should improve above 1.5 if either a pullback creates a better entry or upside targets are raised. | →Stable |
| CounterA stock making new highs on a beat streak can keep re-rating higher, making backward-looking asymmetry math too conservative for a genuine momentum leader. | ||
Nutex has beaten earnings estimates in 3 of the last 4 quarters with an average surprise of 106.65%, and the next report on 2026-07-30 is a near-term catalyst. Earnings | The beat streak should extend at the 2026-07-30 report to confirm continued earnings momentum. | →Stable |
| CounterA miss already broke the streak this cycle on 2026-03-05, showing beats are not guaranteed and volatility around prints is high. | ||
The stock is overbought with an RSI of 87 while trading near its 52-week high, a setup historically associated with short-term pullback risk even in strong uptrends. Momentum breakdown | RSI should cool back toward the 50-70 range within a quarter without a disorderly price decline. | →Stable |
| CounterOverbought conditions in a strong uptrend with rising on-balance volume can persist for extended periods rather than reverting, especially heading into a positive catalyst. | ||
Short interest stands at 26% of float, creating a short-squeeze setup given the company's above-average quality score, per the engine's risk notes. Key risks | Short interest should decline from 26% if the thesis proves out, or a squeeze could accelerate price gains. | →Stable |
| CounterPersistently high short interest can also reflect informed skepticism about the sustainability of the company's reimbursement-driven earnings model, not just a squeeze opportunity. | ||
Nutex Health is a high-quality business with excellent ROE (54%) and cash conversion (175% FCF/NI), backed by a perfect Piotroski F-Score of 9/9.
→StableQuality breakdown
- Expectation
- ROE should stay above 40% and the Piotroski F-Score should hold at 8 or above over the next 12 months to confirm quality durability.
CounterExtremely high ROE at a $1.4B market cap in a niche healthcare facility model can reflect leverage or a concentrated reimbursement mix rather than a durable moat, and could compress quickly if payer rates shift.
At the current price near its 52-week high, the risk/reward has compressed to just 9.1% modeled upside against 15% downside, an asymmetry ratio of only 0.61 that failed the engine's 1.5 minimum threshold.
→StableReward-to-risk math
- Expectation
- Asymmetry ratio should improve above 1.5 if either a pullback creates a better entry or upside targets are raised.
CounterA stock making new highs on a beat streak can keep re-rating higher, making backward-looking asymmetry math too conservative for a genuine momentum leader.
Nutex has beaten earnings estimates in 3 of the last 4 quarters with an average surprise of 106.65%, and the next report on 2026-07-30 is a near-term catalyst.
→StableEarnings
- Expectation
- The beat streak should extend at the 2026-07-30 report to confirm continued earnings momentum.
CounterA miss already broke the streak this cycle on 2026-03-05, showing beats are not guaranteed and volatility around prints is high.
The stock is overbought with an RSI of 87 while trading near its 52-week high, a setup historically associated with short-term pullback risk even in strong uptrends.
→StableMomentum breakdown
- Expectation
- RSI should cool back toward the 50-70 range within a quarter without a disorderly price decline.
CounterOverbought conditions in a strong uptrend with rising on-balance volume can persist for extended periods rather than reverting, especially heading into a positive catalyst.
Short interest stands at 26% of float, creating a short-squeeze setup given the company's above-average quality score, per the engine's risk notes.
→StableKey risks
- Expectation
- Short interest should decline from 26% if the thesis proves out, or a squeeze could accelerate price gains.
CounterPersistently high short interest can also reflect informed skepticism about the sustainability of the company's reimbursement-driven earnings model, not just a squeeze opportunity.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Nutex Health is a high-quality business with an excellent earnings track record, but the risk/reward has compressed near its 52-week high, leaving thin modeled upside despite a supportive short-squeeze setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
8.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 6.1 |
| Op margin | 10.0 |
| Net margin | 5.5 |
| Current ratio | 9.9 |
| FCF quality | 10.0 |
| Moat | 7.1 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 54%
- ▸Excellent cash conversion: 175% FCF/NI
- ▸Strong Piotroski F-Score: 9/9
- ▸High-quality business
Growth
6.5/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.0 |
| EPS growth | 10.0 |
Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 4.0 |
- ▸Overbought (RSI 73)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 9.0 |
| erm sentiment | 4.8 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 37%
Insider
7.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.6 |
| quality rank | 9.4 |
| growth rank | 2.0 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.5 |
| support resistance | 3.4 |
| 52w position | 7.6 |
| gap | 6.0 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 10.0 |
| days to cover | 1.5 |
| volatility | 0.0 |
| beta | 3.4 |
| debt equity | 6.3 |
- ▸Short squeeze setup: 26% short, quality 7.5
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality-value play. Wait for momentum improvement.
Engine technical detail
verdict_path:
L4:PATH_C_QUALITY_VALUE_WAIT|ENTRY_STICKY:WITHIN_BANDPassed (7)
- MOMENTUM:5.7>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:23d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.3<1.5@spot
Warning (0)
none
Reward-to-Risk
1.29
Upside
+19.4%
Downside
15.0%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 23d with 3/4 beat streak
SuitabilityAggressive — Beta 1.97>1.3, MCap $1.3B<$5B
Investment implication
The C-path quality+value combination triggered the STRONG_BUY_WAIT verdict: quality 8.7 and value 9.0 both clear their thresholds, with asymmetric R:R of 1.29 supporting the read.
The strongest dimensions are Value at 9.0, Quality at 8.7, and Insider at 7.5; the weakest are Risk (lower is worse) at 4.2, Technical at 4.9, and Peer rank at 5.2. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.29 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Roe Cash Conversion
Trip ifROE falls below 25% or the Piotroski F-Score drops below 6 for 2 consecutive quarters.
- P2Thin Upside Asymmetry Failure
Trip ifAsymmetry ratio stays below 1.0 for 2 consecutive quarters as the price continues to compress toward its take-profit target.
- P3Earnings Beat Streak Catalyst
Trip ifEPS surprise falls below 0% at the 2026-07-30 report, adding a second miss within the last 5 quarters.
- P4Overbought Technical Setup Near Highs
Trip ifRSI stays above 80 while price falls more than 10% from the current level within 1 quarter.
- P5High Short Interest Squeeze Setup
Trip ifShort interest rises above 30% of float while price momentum turns negative for 2 consecutive months.